SCHEMBL13485083

SCHEMBL13485083

CCOc1cc(OC)cc(OCC)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.61
ESR1 P03372 2/20 0.59
AHR P35869 2/20 0.59
NQO1 P15559 1/20 0.52
CALM1 P0DP23 1/20 0.48
CYP1A1 P04798 3/20 0.46
CYP1B1 Q16678 3/20 0.46
ABL1 P00519 1/20 0.44
ABCB1 P08183 1/20 0.44
BCR P11274 1/20 0.44
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
POLB P06746 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP3A4 P08684 2/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2E1 P05181 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13074291 1.00 ALDH1A1 (0.61) ALDH1A1ESR1AHRNQO1CALM1
SCHEMBL14461578 0.91 ESR1 (0.52) ALDH1A1ESR1AHRNQO1CALM1
SCHEMBL10979139 0.89 ESR1 (0.50) ALDH1A1ESR1AHRNQO1CALM1
SCHEMBL14832881 0.89 CYP3A4 (0.53) ALDH1A1ESR1AHRNQO1CALM1
SCHEMBL9278662 0.89 CALM1 (0.51) ALDH1A1ESR1AHRNQO1CALM1
SCHEMBL13189262 0.89 CALM1 (0.50) ALDH1A1ESR1AHRNQO1CALM1
SCHEMBL12093390 0.89 ESR1 (0.50) ALDH1A1ESR1AHRNQO1CALM1
SCHEMBL28106724 0.89 ESR1 (0.50) ALDH1A1ESR1AHRNQO1CALM1
SCHEMBL1683212 0.88 NQO1 (0.65) ALDH1A1ESR1AHRNQO1MAPT
SCHEMBL8264227 0.85 CALM1 (0.47) ALDH1A1ESR1AHRNQO1CALM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016124304-A1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2016-08-11 WO disclosed
US-7666898-B2 Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors ILYPSA, INC. (US) 2010-02-23 US disclosed
US-20070135385-A1 Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction ILYPSA, INC. 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135385-A1 Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction GPR119, INMT, PNLIP ALDH1A1 2180/4885ESR1 4236/4885AHR 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.